Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on psychiatry and other central nervous system disorders. Founded in 2019 and based in Mountain View, California, it is building a Precision Psychiatry Platform that uses neurobiology and data science to identify biomarkers and match patients to treatments more likely to work for them. The company’s pipeline includes seven clinical-stage assets across major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s disease. Alto is still in development mode, with no commercial products and no internal manufacturing footprint, and relies on third-party partners for clinical supply and future commercialization support.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueProprietary neurobiology and data-science tools used to identify biomarkers and stratify patients for clinical development.
Investigational therapies targeting depression, schizophrenia, and Parkinson’s disease across multiple mechanisms.
Customers
Alto does not currently sell commercial products, so its near-term customers are primarily clinical trial participants, investigators, and research sites that support development of its drug candidates. If approved, the company expects to sell into psychiatry and neurology treatment markets, where physicians prescribe therapies for patients with major depressive disorder, treatment-resistant depression, bipolar depression, schizophrenia, and Parkinson’s disease. The company’s precision approach is designed to appeal to clinicians and payers seeking better response rates in heterogeneous patient populations. Alto also expects to work with commercialization partners outside the United States, suggesting future customers may include regional pharmaceutical partners and distributors.
Patients enrolled in Alto’s studies for MDD, schizophrenia, TRD, bipolar depression, and Parkinson’s disease to generate efficacy and biomarker data.
Hospitals, clinics, and trial sites that administer protocols and collect data needed to advance the pipeline.
Future prescribers who would use Alto’s approved products if development succeeds, especially in hard-to-treat CNS disorders.
Potential licensing or commercialization partners, especially outside the United States, that could help launch approved products.
Strategy
Alto’s strategy is to build a differentiated psychiatry pipeline around biomarker-based patient stratification rather than the traditional all-comer model. The company is prioritizing clinical development of its most advanced assets, including ALTO-207, while also advancing ALTO-101, ALTO-202, and ALTO-208 into later-stage planning and testing. It is trying to preserve capital by reducing headcount and re-deploying savings toward the highest-priority programs. Alto also intends to keep commercialization flexible, using internal capabilities in the U.S. and opportunistic partnerships abroad if products reach approval.
The company has no commercial revenue, so value creation depends on generating positive clinical data and moving assets toward regulatory milestones.
As a clinical-stage company with limited resources, Alto needs to concentrate spending on programs with the best probability of value creation.
Biomarker-based patient selection is intended to improve clinical success rates and create a competitive moat versus untargeted CNS drug development.
If products are approved, Alto will need a scalable launch model and may need partners outside the U.S. to reach global markets efficiently.
Geography
Alto is headquartered in Mountain View, California and is incorporated in Delaware, with operations centered in the United States. The company’s current development work is primarily U.S.-based, including clinical operations, management, and oversight of third-party manufacturers and CROs. Management has said it may pursue commercialization partnerships outside the United States, which would broaden geographic exposure if any product is approved. No country-level revenue disclosure is available because the company has not commercialized products.
Risks
Alto faces the core risks of a clinical-stage biopharmaceutical company: no approved products, no commercial revenue, and a high probability that one or more programs may fail in development. Its precision psychiatry strategy depends on identifying biomarkers that translate into better outcomes, but clinical results may not replicate across heterogeneous CNS populations. The company also relies heavily on CROs, CMOs, and other third parties, so trial execution, supply continuity, and data integrity are operationally critical. In addition, competition in neuropsychiatry is intense, and larger companies may have more capital, broader development capabilities, and stronger commercialization infrastructure. Cybersecurity, intellectual property, and funding needs are also material because Alto must protect sensitive clinical data, defend its asset rights, and raise substantial additional capital over time.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on positive data from seven clinical-stage assets, and any trial setback could materially reduce pipeline value.
Exposure - Funding and dilution riskImpact: HighLikelihood: High
Alto expects to need substantial additional capital to fund operations and clinical development beyond its current runway.
Exposure: Company-wide
- Third-party trial and manufacturing dependenceImpact: HighLikelihood: Medium
The company relies on CROs and CMOs for clinical execution and supply, so delays or quality issues can slow development.
Exposure: Clinical trials and clinical supply chain
- Competitive pressure in CNS drug developmentImpact: HighLikelihood: Medium
Larger biopharma and biotech competitors may reach approval faster or commercialize more effectively in psychiatry and neuroscience.
Exposure - Cybersecurity and data privacyImpact: MediumLikelihood: Low
Clinical and biomarker data are sensitive, and breaches or system disruptions could impair trials and damage trust.
Exposure
Accounting
Judgemental itemsManagement must estimate unbilled CRO, site, and vendor costs, which directly affects reported operating expenses and liabilities.
Impact: Can move quarterly R&D expense and accrued liabilities materially
License and asset purchase agreements may trigger future payments if development milestones are achieved.
Impact: Can create contingent liabilities and cash outflows
As a development-stage company, equity awards are an important part of compensation and depend on valuation assumptions.
Impact: Affects G&A and R&D expense
Enrollment timing, trial starts, and program prioritization can shift expenses between quarters.
Impact: Makes period-to-period comparisons less stable
Similar listed companies
Publicly listed companies with a comparable business focus.
Firefly Neuroscience, Inc
AIFF · Services-Prepackaged Software
Alto Ingredients, Inc.
ALTO · Industrial Organic Chemicals
Silo Pharma, Inc.
SILO · Pharmaceutical Preparations
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Jupiter Neurosciences, Inc
JUNS · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Last updated: 24/09/2026